IMMUNOVANT INC

About

ImImmunoVant Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for the treatment of autoimmune diseases. The company's primary product candidate, IMVT-1401, is designed to inhibit the neonatal Fc receptor (FcRn) to address conditions driven by pathogenic IgG antibodies. By targeting specific immunological pathways, ImmunoVant aims to provide differentiated therapies for patients with unmet medical needs in the autoimmune sector.